Anzeige
Mehr »
Dienstag, 27.01.2026 - Börsentäglich über 12.000 News
1 Billion Dollar reichen nicht: Europas kritisches Rohstoffproblem
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PQ7G | ISIN: SE0012853455 | Ticker-Symbol: 6EQ
Tradegate
27.01.26 | 18:16
33,050 Euro
-0,90 % -0,300
1-Jahres-Chart
EQT AB Chart 1 Jahr
5-Tage-Chart
EQT AB 5-Tage-Chart
RealtimeGeldBriefZeit
33,03033,15019:02
33,03033,15019:02

Aktuelle News zur EQT AB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10:18EQT Foundation opens applications for breakthrough science grants to reduce dependence on critical minerals for the green transition206EQT Foundation opens applications for deeptech solutions grants, tackling critical mineral dependence in climate technologiesThe program will award between EUR 25,000 and EUR 100,000STOCKHOLM...
► Artikel lesen
MoEinstieg ins Secondaries-Geschäft: EQT erwirbt Coller Capital7
FrEQT kauft Secondaries-Gigant Coller Capital für 3,2 Milliarden Dollar6
FrSweden's EQT Leans Into Secondaries Story, Agrees Coller Capital Bid2
DoColler Capital To Become Part Of EQT's Global Platform3
DoSweden's EQT to buy secondaries firm Coller Capital for up to $3.7bn5
DoEQT To Acquire Coller Capital In $3.2 Billion Share Deal, Launching New Secondaries Segment2
EQT AB Aktie jetzt für 0€ handeln
DoEQT to acquire Coller Capital in deal valued at up to $3.7bn3
DoEQT strikes $3.2bn deal for Coller Capital to enter secondaries market6
DoEQT AB Non-GAAP EPS of €1.12, revenue of €2.73B3
DoEQT To Buy Coller Capital For Initial $3.2 Bln345LONDON (dpa-AFX) - EQT AB (EQT.ST, EQBBF), a Swedish investment company, said on Thursday that it has inked a deal to acquire Coller Capital, a British private equity company, for a base consideration...
► Artikel lesen
DoEQT AB (publ) Year-end Report 20252942025 - A year of strong executionSTOCKHOLM, Jan. 22, 2026 /PRNewswire/ -- "2025 was a year of great progress and strong execution for EQT. We navigated a volatile market environment, achieved...
► Artikel lesen
DoEQT AB FY25 Net Income Down On Weak Revenues; EBITDA, Margin Rise; To Buy Coller Capital289STOCKHOLM (dpa-AFX) - EQT AB (EQT.ST), a Swedish investment company, reported Thursday that its fiscal 2025 net profit declined from last year with weak revenues. However, EBITDA, a key earnings...
► Artikel lesen
DoEQT AB Reports Decline In H2 Bottom Line224STOCKHOLM (dpa-AFX) - EQT AB (EQT.ST) reported earnings for second half that Drops, from last yearThe company's bottom line came in at EUR382 million, or EUR0.325 per share. This compares with...
► Artikel lesen
DoEQT to combine with Coller Capital to enter secondaries, marking the next step in EQT's strategic evolution547EQT to acquire Coller Capital, a leading global secondaries firm with nearly USD 50 billion in total assets under management1 across institutional, private wealth and insurance-related capitalThe...
► Artikel lesen
MiEQT plans venture continuation fund as secondaries expand3
20.01.EQT Life Sciences Co-leads 51 Mln EUR Funding Of Exciva's Deraphan For Alzheimer's Disease337STOCKHOLM (dpa-AFX) - EQT AB (EQBBF,EQT.ST), an equity and venture capital firm under the life sciences category, announced that its LSP Dementia Fund has co-led a 51 million euros Series B...
► Artikel lesen
20.01.EQT Life Sciences co-leads €51 million funding for Alzheimer's therapy9
20.01.Alzheimer-Therapie: Exciva sichert sich 51 Millionen Euro unter Führung von EQT Life Sciences4
20.01.EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2160Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD)Financing was co-led by EQT Life Sciences...
► Artikel lesen
Weiter >>
305 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2